Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety

Inclusion Criteria:

• A history suggestive of immediate allergy to the food. A convincing clinical historyof an IgE mediated reaction to a specific food will be defined as a minimum of 2 mildsigns/symptoms or 1 moderate or 1 severe sign/symptom that was likely IgE mediated andoccurred within 120 minutes after ingestion or contact
• The presence of at least one of the following confirmatory tests:
• Positive SPT to the culprit food allergen (weal diameter 3 mm larger than that ofthe normal saline control). The allergens used will be commercial extracts of thefoods (Omega Labs, Toronto, Ontario).
• Detection of serum specific IgE (>0.35 kU/L) to the culprit food or any of itsproteins, measured by fluorescence enzyme immunoassay (Phadia, CAP System,Uppsala, Sweden).

Exclusion Criteria:

• Patients who have uncontrolled respiratory disease (asthma, cystic fibrosis, etc.)
• Patients who present with intercurrent disease active at the time of startingdesensitization.
• Non IgE mediated or non-immunological adverse reactions to milk or peanuts.
• Malignant or immunopathological diseases and/or severe primary or secondary immunedeficiencies.
• Patients receiving oral immunosuppressor therapy.
• Patients receiving β-blockers (including topical formulations), or who receive dailydoses of NSAIDs, aspirin or ACE inhibitors for cardiac issues.
• Associated diseases contraindicating the use of epinephrine: cardiovascular disease,severe hypertension or hypotension.
• Patients diagnosed with eosinophilic gastrointestinal disorders, including patientswith a history of antacid use for reflux related to food impaction or with a historyof esophageal spasm.
• Patients already tolerating processed/cooked forms of the food (e.g.,baked goods withmilk).